{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
nalidixic acid
to a specific field?
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Efletirizine is histamine H1 receptor antagonist. Restricted to topical use. It was under investigation in Phase III (in Europe) clinical studies for the treatment of allergic rhinitis and chronic idiopathic urticarial. Research was discontinued in 2005 due to limited clinical efficacy and safety data. Efletirizine also reduced ocular itching.
Status:
Investigational
Source:
NCT02179814: Not Applicable Interventional Suspended Bulimia Nervosa
(2012)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Racemetirosine is an orally active inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamine. At dosages of 600 to 3500mg daily, it is effective in controlling the hypertensive episodes and symptoms of catecholamine excess in phaeochromocytoma during preparation for surgery. Oral Racemetirosine is well absorbed and absorption appears constant in each individual over a wide dosage range. The drug is largely excreted via the kidneys, but extrarenal elimination has not been studied. Case reports on the clinical use of Racemetirosine in phaeochromocytoma indicate that the drug controls hypertension and symptoms of catecholamine excess in most patients during preparation for surgical removal of a tumor. In some cases, the addition of Racemetirosine to phenoxybenzamine plus propranolol has resulted in adequate control of symptoms previously unresponsive to the adrenergic blocking regimen. Drowsiness and sedation have been the most frequently reported side effects of Racemetirosine treatment.
Status:
Investigational
Source:
INN:potassium nitrazepate [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Nitrazepate is the diazepam derivative. Nitrazepate is tranquiliser.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Dimethiodal is the diagnostic aid (radiopaque medium). Dimethiodal sodium was the chemical analog of methiodal sodium with two instead of one iodine atom per molecule. It is an uro-angiographic contrast agent that, together with methiodal sodium, iodomethamate disodium and iodopyracet diethanolamine, dominated the market in 1930s and 1940s.
Class (Stereo):
CHEMICAL (ACHIRAL)
Nicafenine, a quinoline derivative, is an analgesic.
Class (Stereo):
CHEMICAL (ACHIRAL)
FLUFOSAL is an antithrombotic agent.
Class (Stereo):
CHEMICAL (RACEMIC)
Doxaprost is an orally active bronchodilator. Doxaprost was 73 and 32 times more potent that (+/-) 11-deoxy PGE1 by the aerosol and i.v. routes, respectively. Doxaprost also demonstrated a longer duration of effect. Doxaprost is indicated for the treatment of symptoms of benign prostatic hyperplasia and hypertension. Common side effects are: dizziness, weakness and rarely fainting, especially at the beginning of the medication use. Doxaprost potentiates the action of lowering the blood pressure of other alpha-blockers and anti-hypertensives.
Class (Stereo):
CHEMICAL (ACHIRAL)
Drazidox is the antiseptic agent.
Status:
Investigational
Source:
NCT00065312: Phase 2 Interventional Completed Diabetes Mellitus, Non-Insulin-Dependent
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Naveglitazar is an oral dual peroxisome proliferator-activated receptor (PPAR) agonist, which was under development with Ligand Pharmaceuticals for the treatment of type 2 diabetes mellitus. Naveglitazar is a nonthiozolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual, γ-dominant agonist that has shown glucose-lowering potential in animal models and in the clinic. Naveglitazar had been in phase II clinical trials for the once-daily oral treatment of type 2 diabetes, however, the development was discontinued.
